Neurocrine Biosciences, Inc. (NBIX) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $142.70 -0.41%
Revenue Growth %: +30.8%
Financial Fact:
General and administrative: 17.49M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +30.8%
Financial Fact:
General and administrative: 17.49M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported Q2 EPS of ($0.18), in-line with the analyst estimate of ($0.18).
For earnings history and earnings-related data on Neurocrine Biosciences, Inc. (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Pfizer's 25-valent pneumococcal vaccine shows Phase 2 results
- Truist names top clean energy stocks to watch ahead of Q3 earnings season
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
